Novo Nordisk A/S (NVO): Price and Financial Metrics


Novo Nordisk A/S (NVO)

Today's Latest Price: $72.03 USD

1.00 (1.41%)

Updated Jan 15 7:00pm

Add NVO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVO Stock Summary

  • NVO has a higher market value than 98.85% of US stocks; more precisely, its current market capitalization is $167,481,637,000.
  • Novo Nordisk A S's stock had its IPO on January 1, 1986, making it an older stock than 92.8% of US equities in our set.
  • In terms of volatility of its share price, NVO is more volatile than just 0.8% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novo Nordisk A S are MDT, DHR, SAP, TXN, and LLY.
  • NVO's SEC filings can be seen here. And to visit Novo Nordisk A S's official web site, go to www.novonordisk.com.

NVO Stock Price Chart Interactive Chart >

Price chart for NVO

NVO Price/Volume Stats

Current price $72.03 52-week high $73.92
Prev. close $71.03 52-week low $49.24
Day low $71.39 Volume 1,011,600
Day high $72.29 Avg. volume 1,074,580
50-day MA $69.21 Dividend yield 1.03%
200-day MA $66.78 Market Cap 169.62B

Novo Nordisk A/S (NVO) Company Bio


Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. The company was founded in 1925 and is based in Bagsvaerd, Denmark.

NVO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$72.03$127.23 77%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Novo Nordisk A S. To summarize, we found that Novo Nordisk A S ranked in the 65th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for NVO, they are:

  • In the past 4.74 years, Novo Nordisk A S has a compound free cash flow growth rate of 0.03%; that's higher than only 23.4% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than just 3.84% of the free cash flow producing stocks we're observing.
  • NVO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 57.11% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%73%
1%75%
2%77%
3%78%
4%80%
5%82%

Want more companies with a valuation profile/forecast similar to that of Novo Nordisk A S? See FMS, DVA, FZMD, PNTG, and DGX.


NVO Latest News Stream


Event/Time News Detail
Loading, please wait...

NVO Latest Social Stream


Loading social stream, please wait...

View Full NVO Social Stream

Latest NVO News From Around the Web

Below are the latest news stories about Novo Nordisk A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.

Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

Novo Nordisk A/S (NVO) 39th Annual JPMorgan Virtual Healthcare Conference January 12, 2021 09:10 AM ET Company Participants Lars Fruergaard Jørgensen - CEO Conference Call Participants Richard Vosser - JPMorgan Presentation Richard Vosser Good morning. Good afternoon. Welcome to the 39th JPMorgan Healthcare Conference. I’m Richard Vosser, European Pharma Analyst...

SA Transcripts on Seeking Alpha | January 12, 2021

Hemophilia Treatment Market | Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG.

CMI published a business research report on “Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2020–2027”. Hemophilia Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand

OpenPR | January 12, 2021

Global Biotechnology Services Market Report 2020-2030 Featuring Leading Players - Novartis, Fisher BioService, Pfizer, Novo Nordisk, BioAlps, Precision for Medicine, Sartorius and Aldevron - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Biotechnology Services Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering. Biotechnology Services Global Market Report 2020-30: COVID-19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global biotechnology services market. Major players in the biotechnology services market are Novartis, Fisher BioService, Pfizer, Novo N

Business Wire | January 7, 2021

Special Purpose Needles Market Share and Outlook | Boston Scientific Corporation, Argon Medical Devices, Inc., Becton, Dickinson and Company, Cook Medical, B. Braun Melsungen AG, Medtronic Plc., Novo Nordisk A/S, SERAG-WIESSNER GmbH & Co.,

The global Special Purpose Needles Market research report thoroughly explains each and every aspect related to the Special Purpose Needles Market, which facilitates the report’s reader to study and evaluate the upcoming market trend and execute the analytical data to

OpenPR | January 7, 2021

Dicerna Announces Novo Nordisk’s Nomination of First Candidate for Development Under RNAi Discovery and Development Agreement and Additional Milestone Achievement

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Novo Nordisk has nominated its first candidate for development under the existing agreement between the two companies.

Business Wire | January 5, 2021

Read More 'NVO' Stories Here

NVO Price Returns

1-mo -2.40%
3-mo 1.67%
6-mo 9.05%
1-year N/A
3-year 31.18%
5-year 48.16%
YTD 3.12%
2020 22.56%
2019 27.79%
2018 -12.54%
2017 52.92%
2016 -37.03%

NVO Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVO Dividend History

Continue Researching NVO

Want to see what other sources are saying about Novo Nordisk A S's financials and stock price? Try the links below:

Novo Nordisk A S (NVO) Stock Price | Nasdaq
Novo Nordisk A S (NVO) Stock Quote, History and News - Yahoo Finance
Novo Nordisk A S (NVO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9516 seconds.